【摘要】：目的觀察厄貝沙坦片聯(lián)合精蛋白生物合成人胰島素注射液治療老年2型糖尿病腎病患者的臨床療效及安全性。方法將100例老年2型糖尿病腎病患者隨機(jī)分為對照組50例和試驗(yàn)組50例。對照組予以精蛋白生物合成人胰島素0.25 U·kg~(-1)·d~(-1),bid,早餐和晚餐前皮下注射;試驗(yàn)組在對照組治療的基礎(chǔ)上,予以厄貝沙坦150 mg,qd,口服。2組患者均治療3個月。比較2組患者的臨床療效、血尿素氮(BUN)、血清肌酸酐(SCr)、24 h尿白蛋白排泄率(24 h UAER),以及藥物不良反應(yīng)的發(fā)生情況。結(jié)果治療后,試驗(yàn)組和對照組的總有效率分別為94.00%(47/50例)和76.00%(38/50例),差異有統(tǒng)計(jì)學(xué)意義(P0.05)。治療后,試驗(yàn)組和對照組的BUN分別為(6.84±0.56)和(7.67±0.70)mmol·L~(-1),SCr分別為(76.49±8.05)和(86.39±8.04)μmol·L~(-1),24 h UAER分別為(68.02±6.75)和(78.70±7.52)mg·24 h~(-1),差異均有統(tǒng)計(jì)學(xué)意義(均P0.05)。2組患者的藥物不良反應(yīng)以頭痛、眩暈、心悸、咳嗽為主,且試驗(yàn)組和對照組的藥物不良反應(yīng)率分別為16.00%和22.00%,差異無統(tǒng)計(jì)學(xué)意義(P0.05)。結(jié)論厄貝沙坦片聯(lián)合精蛋白生物合成人胰島素注射液治療老年2型糖尿病腎病的臨床療效確切,其能有效地改善患者的腎功能,且不增加藥物不良反應(yīng)的發(fā)生率。
[Abstract]:Objective to observe the clinical efficacy and safety of irbesartan tablets combined with protamine biosynthetic human insulin injection in the treatment of elderly patients with type 2 diabetic nephropathy. Methods 100 elderly patients with type 2 diabetic nephropathy were randomly divided into control group (n = 50) and experimental group (n = 50). The control group was subcutaneously injected with human insulin 0.25 U kg~ (-1) D1), bid, before breakfast and dinner. The experimental group was treated with irbesartan for 150 mg,qd, on the basis of control group. The patients in both groups were treated for 3 months. The clinical efficacy, urinary albumin excretion rate (24 h UAER),) and adverse drug reaction (ADR) of serum creatinine (SCr), (24 h UAER),) in serum urea nitrogen (BUN),) were compared between the two groups. Results after treatment, the total effective rates of the experimental group and the control group were 94.00% (47 / 50 cases) and 76.00% (38 / 50 cases), respectively. The difference was statistically significant (P0.05). After treatment, the BUN of the experimental group and the control group were (6.84 鹵0.56) and (7.67 鹵0.70) mmol L ~ (-1), SCr, respectively (76.49 鹵8.05) and (86.39 鹵8.04) 渭 mol L ~ (-1), respectively. 24 h UAER were (68.02 鹵6.75) and (78.70 鹵7.52) mg 24 h ~ (-1), respectively, the difference was statistically significant (P0.05). The adverse drug reactions of the two groups were headache, dizziness, palpitation and cough. The adverse drug reaction rates in the test group and the control group were 16.00% and 22.00%, respectively, with no significant difference (P0.05). Conclusion Irbesartan tablet combined with protamine biosynthetic human insulin injection is effective in the treatment of senile type 2 diabetic nephropathy. It can effectively improve the renal function of the patients without increasing the incidence of adverse drug reactions.
【作者單位】： 杭州市第三人民醫(yī)院腎內(nèi)科;
【基金】：浙江省醫(yī)藥衛(wèi)生計(jì)劃基金資助項(xiàng)目(2011ZHA003)
【分類號】：R587.2;R692.9

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 邢志華;郝麗萍;;早發(fā)2型糖尿病患者短期重組人門冬脯胰島素注射液強(qiáng)化治療的臨床分析[J];山西醫(yī)科大學(xué)學(xué)報(bào);2006年10期

2 丁瓊;;門冬胰島素注射液30強(qiáng)化治療初診2型糖尿病臨床觀察[J];吉林醫(yī)學(xué);2012年01期

3 王立秋;胰島素注射液引起肌肉萎縮1例[J];中國醫(yī)院藥學(xué)雜志;1995年06期

4 范蓓蓓;曲虹;夏云;;腎康注射液與生物合成人胰島素注射液合用致神經(jīng)系統(tǒng)不良反應(yīng)1例[J];中南藥學(xué);2012年05期

5 易賢明;;常用胰島素注射液差異性在糖尿病治療中的應(yīng)用研究[J];中國醫(yī)藥導(dǎo)刊;2012年10期

6 操秋蓮;袁俊華;;門冬胰素島30注射液和精蛋白生物合成人胰島素注射液(預(yù)混30R)治療老年2型糖尿病的護(hù)理[J];實(shí)用臨床醫(yī)學(xué);2012年03期

7 王瑩;虞成畢;陳勇;張美珍;;門冬胰島素注射液肌內(nèi)注射避免胰島素過敏反應(yīng)一例[J];江西醫(yī)學(xué)院學(xué)報(bào);2009年08期

8 李彩娜;孫素娟;劉率男;劉泉;申竹芳;;國產(chǎn)門冬胰島素注射液在正常動物中降血糖作用的評價[J];中國糖尿病雜志;2014年04期

9 紀(jì)鳳敏;支文艷;黃會英;魯亞茹;;醫(yī)院使用中的精蛋白生物合成人胰島素注射液貯存方法的調(diào)查分析[J];護(hù)理研究;2010年25期

10 劉太圣;;不同胰島素注射液在糖尿病治療中的應(yīng)用研究[J];臨床合理用藥雜志;2013年15期

相關(guān)會議論文 前1條

1 歐陽碧岷;游春華;;糖尿病酮癥酸中毒26例治療體會[A];第六次中國中西醫(yī)結(jié)合糖尿病學(xué)術(shù)會議論文匯編[C];2002年

，

本文編號：2381796